Premium
Chlorambucil vs. combined chlorambucil‐corticosteroid therapy in chronic lymphocytic leukemia
Author(s) -
Han Tin,
Ezdinli Ediz Z.,
Shimaoka Katsutaro,
Desai Dinesh V.
Publication year - 1973
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197303)31:3<502::aid-cncr2820310303>3.0.co;2-7
Subject(s) - chlorambucil , prednisone , medicine , chronic lymphocytic leukemia , gastroenterology , chemotherapy , complete remission , corticosteroid , leukemia , cyclophosphamide
Eleven patients with chronic lymphocytic leukemia were treated with chlorambucil alone and 15 patients received combined chlorambucil‐prednisone therapy in a double‐blind study. Mean age, duration of disease, physical findings, and hematologic data in the two groups were essentially comparable. Complete remission was observed in 3 and partial remission in 10 of the patients in the chlorambucil‐prednisone treated group; but only one of the patients obtained complete and four showed partial remission with chlorambucil alone. This difference was statistically significant (p < 0.05). Hematologic toxicity was less frequent in the combination group. Two‐year survival was 93% for combination group and 54% for chlorambucil‐treated group. The difference, however, was not statistically significant. Our data indicate that chlorambucil‐prednisone therapy is superior to chlorambucil in the treatment of chronic lymphocytic leukemia.